Role of central arginine vasopressin receptors in the analgesic effect of CDP-choline on acute and neuropathic pain

Bagdas D., Yucel-Ozboluk H., Orhan F., Kanat O., Isbil-Buyukcoskun N., GÜRÜN M. S.

NEUROREPORT, vol.24, no.17, pp.941-946, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 17
  • Publication Date: 2013
  • Doi Number: 10.1097/wnr.0000000000000009
  • Journal Name: NEUROREPORT
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.941-946
  • Keywords: acute pain, analgesia, arginine vasopressin, CDP-choline, neuropathic pain, PERIAQUEDUCTAL GRAY, ANTINOCICEPTION, RAT, INVOLVEMENT, NOCICEPTION, NUCLEI, MODELS
  • Bursa Uludag University Affiliated: Yes


Recent studies have demonstrated that arginine vasopressin (AVP) plays a crucial role in pain modulation. In addition, our previous studies have proven that centrally administered cytidine-5-diphosphate-choline (CDP-choline; citicoline) elicits an analgesic effect in different pain models in rats. Given that CDP-choline enhances central and peripheral vasopressin levels, the present study was designed to investigate the role of central AVP receptors in the analgesic effect of CDP-choline in acute and chronic constriction injury-induced neuropathic pain models. For this purpose, rats were pretreated intracerebroventricularly with the AVP V-1 or AVP V-2 receptor antagonist 15 min before intracerebroventricular injection of CDP-choline or saline, and pain threshold was determined using the Randall-Selitto test. AVP V-1 and AVP V-2 receptor antagonist blocked the CDP-choline-induced analgesic effect either in acute or neuropathic models of pain in rats. These results suggest, for the first time, that central AVP receptors are involved in the CDP-choline-elicited analgesic effect. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.